Pub Date : 2025-01-10DOI: 10.1016/j.pnpbp.2024.111246
Agnieszka Mechlińska, Adam Włodarczyk
{"title":"Measuring the effects of ketogenic diet on neuropsychiatric disorder: A scoping review – Letter to the Editor","authors":"Agnieszka Mechlińska, Adam Włodarczyk","doi":"10.1016/j.pnpbp.2024.111246","DOIUrl":"10.1016/j.pnpbp.2024.111246","url":null,"abstract":"","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"136 ","pages":"Article 111246"},"PeriodicalIF":5.3,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-10DOI: 10.1016/j.pnpbp.2025.111250
Mingxuan Lu , Jiayao Zhang , Qi Zhang , Jiyu Sun , Danni Zou , Jinyin Huang , Weicai Liu
Eating behavior stands as a fundamental determinant of animal survival and growth, intricately regulated by an amalgamation of internal and external stimuli. Coordinated movements of facial muscles and the mandible orchestrate prey capture and food processing, propelled by the allure of taste and rewarding food properties. Conversely, satiation, pain, aversion, negative emotion or perceived threats can precipitate the cessation or avoidance of eating activities. In recent years, the parasubthalamic nucleus (PSTN), located in the lateral hypothalamic area, has emerged as a focal point in feeding research. PSTN neurons assume pivotal roles within multiple feeding circuits, bridging central feeding centers with peripheral organs. They intricately modulate regulation of oral sensorimotor functions, hedonic feeding, appetite motivation and the processing of satiation and aversive signals, thereby orchestrating the initiation or termination of feeding behaviors. This review delves into the distinctive neuronal subpopulations within the PSTN and their associated neural networks, aiming to refine our comprehension of the neural underpinnings of feeding while also seeking to unearth more efficacious therapeutic avenues for feeding and eating disorders.
{"title":"The parasubthalamic nucleus: A novel eating center in the brain","authors":"Mingxuan Lu , Jiayao Zhang , Qi Zhang , Jiyu Sun , Danni Zou , Jinyin Huang , Weicai Liu","doi":"10.1016/j.pnpbp.2025.111250","DOIUrl":"10.1016/j.pnpbp.2025.111250","url":null,"abstract":"<div><div>Eating behavior stands as a fundamental determinant of animal survival and growth, intricately regulated by an amalgamation of internal and external stimuli. Coordinated movements of facial muscles and the mandible orchestrate prey capture and food processing, propelled by the allure of taste and rewarding food properties. Conversely, satiation, pain, aversion, negative emotion or perceived threats can precipitate the cessation or avoidance of eating activities. In recent years, the parasubthalamic nucleus (PSTN), located in the lateral hypothalamic area, has emerged as a focal point in feeding research. PSTN neurons assume pivotal roles within multiple feeding circuits, bridging central feeding centers with peripheral organs. They intricately modulate regulation of oral sensorimotor functions, hedonic feeding, appetite motivation and the processing of satiation and aversive signals, thereby orchestrating the initiation or termination of feeding behaviors. This review delves into the distinctive neuronal subpopulations within the PSTN and their associated neural networks, aiming to refine our comprehension of the neural underpinnings of feeding while also seeking to unearth more efficacious therapeutic avenues for feeding and eating disorders.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"136 ","pages":"Article 111250"},"PeriodicalIF":5.3,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-10DOI: 10.1016/j.pnpbp.2024.111240
F.L. Mikulic , M. Sagud , M. Nikolac Perkovic , S. Kudlek Mikulic , L. Ganoci , M. Bajs Janovic , S. Janovic , I. Filipcic Simunovic , A. Mihaljevic Peles , M. Bozicevic , Z. Bradas , N. Pivac
Brain-derived neurotrophic factor (BDNF) is implicated in the etiology of schizophrenia, and peripheral BDNF levels are affected by the short-term antipsychotic treatment. However, the data on their long-term effects on BDNF levels are scarce, and there is no information whether BDNF levels change during sustained remission in relation to values in healthy individuals. The aim of the present study was to compare serum BDNF levels in patients in long-term remission and healthy controls.
This study is an extension of our previous research on the effects of olanzapine and risperidone on serum BDNF in acute-episode patients with schizophrenia. Patients who remained in remission for at least 3 years on the same antipsychotic regimen (40 % of the initial cohort) were included. Symptoms were assessed by the Positive and Negative Syndrome Scale (PANSS). Serum BDNF levels were measured by ELISA in patients in remission (N = 20), evaluated at baseline, after 6 weeks of treatment and after 3 years of treatment, and in healthy individuals (N = 40).
At baseline (p = 0.046) and after 6 weeks of treatment (p = 0.028), patients had significantly lower BDNF levels than controls. However, after 3 years of continuous antipsychotic maintenance treatment, serum BDNF levels were increased compared to baseline and values after 6 weeks of treatment in remitted patients, and were also significantly higher in patients than in healthy controls (p = 0.002).
Antipsychotic medications appear to have distinct effects on serum BDNF levels in short-and long-term treatment. It remains to be determined if such finding may be related to potential neuroprotective effects of antipsychotic maintenance treatment.
{"title":"Long-term effects of antipsychotics on serum BDNF levels in patients with schizophrenia","authors":"F.L. Mikulic , M. Sagud , M. Nikolac Perkovic , S. Kudlek Mikulic , L. Ganoci , M. Bajs Janovic , S. Janovic , I. Filipcic Simunovic , A. Mihaljevic Peles , M. Bozicevic , Z. Bradas , N. Pivac","doi":"10.1016/j.pnpbp.2024.111240","DOIUrl":"10.1016/j.pnpbp.2024.111240","url":null,"abstract":"<div><div>Brain-derived neurotrophic factor (BDNF) is implicated in the etiology of schizophrenia, and peripheral BDNF levels are affected by the short-term antipsychotic treatment. However, the data on their long-term effects on BDNF levels are scarce, and there is no information whether BDNF levels change during sustained remission in relation to values in healthy individuals. The aim of the present study was to compare serum BDNF levels in patients in long-term remission and healthy controls.</div><div>This study is an extension of our previous research on the effects of olanzapine and risperidone on serum BDNF in acute-episode patients with schizophrenia. Patients who remained in remission for at least 3 years on the same antipsychotic regimen (40 % of the initial cohort) were included. Symptoms were assessed by the Positive and Negative Syndrome Scale (PANSS). Serum BDNF levels were measured by ELISA in patients in remission (<em>N</em> = 20), evaluated at baseline, after 6 weeks of treatment and after 3 years of treatment, and in healthy individuals (<em>N</em> = 40).</div><div>At baseline (<em>p</em> = 0.046) and after 6 weeks of treatment (<em>p</em> = 0.028), patients had significantly lower BDNF levels than controls. However, after 3 years of continuous antipsychotic maintenance treatment, serum BDNF levels were increased compared to baseline and values after 6 weeks of treatment in remitted patients, and were also significantly higher in patients than in healthy controls (<em>p</em> = 0.002).</div><div>Antipsychotic medications appear to have distinct effects on serum BDNF levels in short-and long-term treatment. It remains to be determined if such finding may be related to potential neuroprotective effects of antipsychotic maintenance treatment.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"136 ","pages":"Article 111240"},"PeriodicalIF":5.3,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-10DOI: 10.1016/j.pnpbp.2024.111228
Ting-Ting Zhu , Ming-Ming Zhao , Dan Xu , Yi Cai , Guilin Liu , Rumi Murayama , Yong Yue , Jian-Jun Yang , Kenji Hashimoto
Postoperative cognitive dysfunction (POCD) is characterized by a decline in cognitive functions, including memory, attention, and executive abilities, following surgery, with no effective therapeutic drugs currently available. Arketamine, the (R)-enantiomer of ketamine, has shown promise in mitigating cognitive deficits in animal models. In this study, we investigated whether arketamine could ameliorate cognitive deficits in a mouse model of POCD, with a focus on the role of transforming growth factor (TGF)-β1 in its effects. POCD mice displayed cognitive impairments and demyelination in the corpus callosum. A single arketamine injection (10 mg/kg) significantly improved both cognitive function and demyelination in the corpus callosum of POCD mice. Notably, pretreatment with RepSox (10 mg/kg), a TGF-β receptor 1 inhibitor, significantly blocked the beneficial effects of arketamine on cognitive deficits and demyelination. Moreover, intranasal administration of TGF-β1 (3.0 μg/kg) markedly alleviated cognitive impairments and demyelination in POCD mice. These findings suggest that arketamine exerts its effects through a TGF-β1-dependent mechanism, positioning it as a potential therapeutic option for POCD.
{"title":"Arketamine alleviates cognitive impairments and demyelination in mice with postoperative cognitive dysfunction via TGF-β1 activation","authors":"Ting-Ting Zhu , Ming-Ming Zhao , Dan Xu , Yi Cai , Guilin Liu , Rumi Murayama , Yong Yue , Jian-Jun Yang , Kenji Hashimoto","doi":"10.1016/j.pnpbp.2024.111228","DOIUrl":"10.1016/j.pnpbp.2024.111228","url":null,"abstract":"<div><div>Postoperative cognitive dysfunction (POCD) is characterized by a decline in cognitive functions, including memory, attention, and executive abilities, following surgery, with no effective therapeutic drugs currently available. Arketamine, the (<em>R</em>)-enantiomer of ketamine, has shown promise in mitigating cognitive deficits in animal models. In this study, we investigated whether arketamine could ameliorate cognitive deficits in a mouse model of POCD, with a focus on the role of transforming growth factor (TGF)-β1 in its effects. POCD mice displayed cognitive impairments and demyelination in the corpus callosum. A single arketamine injection (10 mg/kg) significantly improved both cognitive function and demyelination in the corpus callosum of POCD mice. Notably, pretreatment with RepSox (10 mg/kg), a TGF-β receptor 1 inhibitor, significantly blocked the beneficial effects of arketamine on cognitive deficits and demyelination. Moreover, intranasal administration of TGF-β1 (3.0 μg/kg) markedly alleviated cognitive impairments and demyelination in POCD mice. These findings suggest that arketamine exerts its effects through a TGF-β1-dependent mechanism, positioning it as a potential therapeutic option for POCD.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"136 ","pages":"Article 111228"},"PeriodicalIF":5.3,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
3,4-Methylenedioxymethamphetamine (MDMA; Ecstasy) is a widely abused recreational drug that has also gained interest for potential clinical applications in mental health. With the growing recognition of gut microbiota's role in mental health, this study examined whether repeated oral MDMA administration could affect gut microbiota in the small intestine, cecum, and colon of male rats. Repeated oral MDMA administration (10 mg/kg/day for 14 days) caused significant changes in the gut microbiota across these regions, with distinct effects observed in each. PICRUSt2 analysis revealed significant alterations in several metabolic pathways in these regions, indicating potential shifts in microbial functional capabilities associated with MDMA treatment. Untargeted metabolomics analysis revealed that MDMA significantly altered levels of two metabolites-ferulic acid and methylmalonic acid-in the colon, without changes in the blood, small intestine, or cecum. Notably, methylmalonic acid levels in the colon positively correlated with Lawsonibacter and Oscillibacter. These findings suggest that repeated oral MDMA treatment can alter gut microbiota composition across intestinal regions, potentially contributing to its pharmacological effects.
{"title":"Effects of 3,4-methylenedioxymethamphetamine on the gut microbiota and metabolites in the small intestine, cecum, and colon of male rats.","authors":"Dan Xu, Akifumi Eguchi, Rumi Murayama, Guilin Liu, Mingming Zhao, Tingting Zhu, Yi Cai, Yong Yue, Xiayun Wan, Yuko Fujita, Chisato Mori, Kenji Hashimoto","doi":"10.1016/j.pnpbp.2024.111223","DOIUrl":"10.1016/j.pnpbp.2024.111223","url":null,"abstract":"<p><p>3,4-Methylenedioxymethamphetamine (MDMA; Ecstasy) is a widely abused recreational drug that has also gained interest for potential clinical applications in mental health. With the growing recognition of gut microbiota's role in mental health, this study examined whether repeated oral MDMA administration could affect gut microbiota in the small intestine, cecum, and colon of male rats. Repeated oral MDMA administration (10 mg/kg/day for 14 days) caused significant changes in the gut microbiota across these regions, with distinct effects observed in each. PICRUSt2 analysis revealed significant alterations in several metabolic pathways in these regions, indicating potential shifts in microbial functional capabilities associated with MDMA treatment. Untargeted metabolomics analysis revealed that MDMA significantly altered levels of two metabolites-ferulic acid and methylmalonic acid-in the colon, without changes in the blood, small intestine, or cecum. Notably, methylmalonic acid levels in the colon positively correlated with Lawsonibacter and Oscillibacter. These findings suggest that repeated oral MDMA treatment can alter gut microbiota composition across intestinal regions, potentially contributing to its pharmacological effects.</p>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":" ","pages":"111223"},"PeriodicalIF":5.3,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-10Epub Date: 2024-11-23DOI: 10.1016/j.pnpbp.2024.111196
Anastasia Ruban, Mikołaj Magnuski, Justyna Hobot, Paweł Orłowski, Aleksandra Kołodziej, Michał Bola, Aneta Brzezicka
Background: Psychedelics have gained increasing interest in scientific research due to their ability to induce profound alterations in perception, emotional processing and self-consciousness. However, the research regarding the functioning of individuals who use psychedelics in naturalistic contexts remains limited.
Aims: Here we aim to explore psychological and neurophysiological differences between naturalistic psychedelics users and non-users in terms of processing of self-related thoughts.
Methods: We use behavioural testing combined with electroencephalography (EEG) with source localisation. To mitigate potential confounding effects of personality traits and personal history which makes one willing to take psychedelics, we compared users to individuals who did not take psychedelics, but are intending to do so in the future. To ensure robustness of our results, we included two datasets collected at two different laboratories.
Results: The results from Dataset I (N = 70) suggest that during self-related thoughts psychedelics users exhibit weaker increases in alpha and beta power in comparison to non-users, primarily in brain regions linked to processing of self-related information and memory (such as posterior cingulate cortex). However, analysis of Dataset II (N = 38) did not replicate the between-group effects, possibly due to the smaller sample size and spatial resolution limitations.
Conclusions: While non-replicability restricts interpretation of our findings, our research expands the ongoing discussion on strength and duration of the psychedelic effects, specifically in brain circuits associated with self-related processing, and its relationship to well-being. Our results fit into growing scepticism about the specificity of the role of default-mode network hubs in changes associated with psychedelics experience.
{"title":"Processing of self-related thoughts in experienced users of classic psychedelics: A source localisation EEG study.","authors":"Anastasia Ruban, Mikołaj Magnuski, Justyna Hobot, Paweł Orłowski, Aleksandra Kołodziej, Michał Bola, Aneta Brzezicka","doi":"10.1016/j.pnpbp.2024.111196","DOIUrl":"10.1016/j.pnpbp.2024.111196","url":null,"abstract":"<p><strong>Background: </strong>Psychedelics have gained increasing interest in scientific research due to their ability to induce profound alterations in perception, emotional processing and self-consciousness. However, the research regarding the functioning of individuals who use psychedelics in naturalistic contexts remains limited.</p><p><strong>Aims: </strong>Here we aim to explore psychological and neurophysiological differences between naturalistic psychedelics users and non-users in terms of processing of self-related thoughts.</p><p><strong>Methods: </strong>We use behavioural testing combined with electroencephalography (EEG) with source localisation. To mitigate potential confounding effects of personality traits and personal history which makes one willing to take psychedelics, we compared users to individuals who did not take psychedelics, but are intending to do so in the future. To ensure robustness of our results, we included two datasets collected at two different laboratories.</p><p><strong>Results: </strong>The results from Dataset I (N = 70) suggest that during self-related thoughts psychedelics users exhibit weaker increases in alpha and beta power in comparison to non-users, primarily in brain regions linked to processing of self-related information and memory (such as posterior cingulate cortex). However, analysis of Dataset II (N = 38) did not replicate the between-group effects, possibly due to the smaller sample size and spatial resolution limitations.</p><p><strong>Conclusions: </strong>While non-replicability restricts interpretation of our findings, our research expands the ongoing discussion on strength and duration of the psychedelic effects, specifically in brain circuits associated with self-related processing, and its relationship to well-being. Our results fit into growing scepticism about the specificity of the role of default-mode network hubs in changes associated with psychedelics experience.</p>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":" ","pages":"111196"},"PeriodicalIF":5.3,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-10DOI: 10.1016/j.pnpbp.2024.111212
Ashley M. Allemeier , Christine Drummond , Bradley Tiefenthaler , Tierney C. Dvorak , Faith N. Holz , Catherine Hume , Rachelle B. Kreger , Chauncella I. Koulibali , Humza A. Khan , Alexa L. Best , Timothy Gee , Grace D. Pedersen , Kevin Glover , Dollar Ganu , Julie Martin , Matthew N. Hill , S. Alisha Epps
Clinically, patients with depression are at a heightened risk for developing epilepsy, and vice versa, suggesting shared mechanisms for this bidirectional comorbidity. Unfortunately, comorbid depression and epilepsy is associated with worsened quality of life and treatment refractoriness, highlighting the need for novel treatment targets and nonpharmacologic supplements to existing therapies. The present study used the Swim-Low Active rat, a well-validated model of depression and epilepsy comorbidity that was selectively bred based on forced swim test behavior, to assess the safety and efficacy of caloric restriction in treating this comorbidity. The study also investigated the role of endocannabinoids in the effects of caloric restriction on the behavioral endpoints and to determine whether there were any sex differences in these effects.
Male rats restricted to approximately 80 % of their daily food intake for an acute 24-h period showed elevated struggling behavior in the Porsolt (Forced) Swim Test and increased latency to pilocarpine-induced seizure; this same caloric restriction yielded a significant increase in hippocampal anandamide levels compared to ad lib rats. These effects were not seen in female rats, although female rats did show anticonvulsant effects of chronic caloric restriction. Administration of 1 mg/kg SR141716 alongside an acute caloric restriction in male rats blocked the antidepressant-like effects of caloric restriction but did not affect seizure responses. Combined, these results suggest caloric restriction may be both safe and modestly effective in benefitting depression- and epilepsy-related behaviors in male SwLo rats, and that the endocannabinoid system may be a promising target for treating this comorbidity.
{"title":"Endocannabinoid involvement in beneficial effects of caloric restriction in a rodent model of comorbid depression and epilepsy","authors":"Ashley M. Allemeier , Christine Drummond , Bradley Tiefenthaler , Tierney C. Dvorak , Faith N. Holz , Catherine Hume , Rachelle B. Kreger , Chauncella I. Koulibali , Humza A. Khan , Alexa L. Best , Timothy Gee , Grace D. Pedersen , Kevin Glover , Dollar Ganu , Julie Martin , Matthew N. Hill , S. Alisha Epps","doi":"10.1016/j.pnpbp.2024.111212","DOIUrl":"10.1016/j.pnpbp.2024.111212","url":null,"abstract":"<div><div>Clinically, patients with depression are at a heightened risk for developing epilepsy, and <em>vice versa</em>, suggesting shared mechanisms for this bidirectional comorbidity. Unfortunately, comorbid depression and epilepsy is associated with worsened quality of life and treatment refractoriness, highlighting the need for novel treatment targets and nonpharmacologic supplements to existing therapies. The present study used the Swim-Low Active rat, a well-validated model of depression and epilepsy comorbidity that was selectively bred based on forced swim test behavior, to assess the safety and efficacy of caloric restriction in treating this comorbidity. The study also investigated the role of endocannabinoids in the effects of caloric restriction on the behavioral endpoints and to determine whether there were any sex differences in these effects.</div><div>Male rats restricted to approximately 80 % of their daily food intake for an acute 24-h period showed elevated struggling behavior in the Porsolt (Forced) Swim Test and increased latency to pilocarpine-induced seizure; this same caloric restriction yielded a significant increase in hippocampal anandamide levels compared to <em>ad lib</em> rats. These effects were not seen in female rats, although female rats did show anticonvulsant effects of chronic caloric restriction. Administration of 1 mg/kg SR141716 alongside an acute caloric restriction in male rats blocked the antidepressant-like effects of caloric restriction but did not affect seizure responses. Combined, these results suggest caloric restriction may be both safe and modestly effective in benefitting depression- and epilepsy-related behaviors in male SwLo rats, and that the endocannabinoid system may be a promising target for treating this comorbidity.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"136 ","pages":"Article 111212"},"PeriodicalIF":5.3,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-10Epub Date: 2025-01-03DOI: 10.1016/j.pnpbp.2024.111243
Zitong Wang, Brett Robbins, Ryan Zhuang, Thaisa Sandini, Rebekah van Bruggen, Xin-Min Li, Yanbo Zhang
Chronic stress exerts profound effects on mental health, contributing to disorders such as depression, anxiety, and cognitive impairment. This study examines the potential of psilocybin to alleviate behavioral despair and cognitive deficits in a rodent model of chronic stress, focusing on the interplay between the Hypothalamic-Pituitary-Adrenal (HPA) axis and the Endocannabinoid System (ECS). Twenty-two male Wistar rats were divided into control and stress groups. Animals within the stress group were exposed to predator odor and chronic social instability to induce chronic stress, and were either sham treated, or given psilocybin. Behavioral assessments were conducted using the Open Field Test, Sucrose Preference Test, Novel Object Recognition, Elevated Plus Maze, and Forced Swimming Test to evaluate locomotion, anhedonia, memory, anxiety, and behavioral despair, respectively. Blood and brain samples were analyzed for biochemical markers. Results indicated that psilocybin significantly reduced stress-induced behavioral despair and cognitive impairments, likely through ECS-mediated downregulation of the HPA axis. These findings suggest that early intervention with psilocybin has sustained beneficial effects on stress-related behavioral and cognitive disturbances, underscoring its potential as a novel therapeutic approach for stress-related mental health disorders.
{"title":"Early psilocybin intervention alleviates behavioral despair and cognitive impairment in stressed Wistar rats.","authors":"Zitong Wang, Brett Robbins, Ryan Zhuang, Thaisa Sandini, Rebekah van Bruggen, Xin-Min Li, Yanbo Zhang","doi":"10.1016/j.pnpbp.2024.111243","DOIUrl":"10.1016/j.pnpbp.2024.111243","url":null,"abstract":"<p><p>Chronic stress exerts profound effects on mental health, contributing to disorders such as depression, anxiety, and cognitive impairment. This study examines the potential of psilocybin to alleviate behavioral despair and cognitive deficits in a rodent model of chronic stress, focusing on the interplay between the Hypothalamic-Pituitary-Adrenal (HPA) axis and the Endocannabinoid System (ECS). Twenty-two male Wistar rats were divided into control and stress groups. Animals within the stress group were exposed to predator odor and chronic social instability to induce chronic stress, and were either sham treated, or given psilocybin. Behavioral assessments were conducted using the Open Field Test, Sucrose Preference Test, Novel Object Recognition, Elevated Plus Maze, and Forced Swimming Test to evaluate locomotion, anhedonia, memory, anxiety, and behavioral despair, respectively. Blood and brain samples were analyzed for biochemical markers. Results indicated that psilocybin significantly reduced stress-induced behavioral despair and cognitive impairments, likely through ECS-mediated downregulation of the HPA axis. These findings suggest that early intervention with psilocybin has sustained beneficial effects on stress-related behavioral and cognitive disturbances, underscoring its potential as a novel therapeutic approach for stress-related mental health disorders.</p>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":" ","pages":"111243"},"PeriodicalIF":5.3,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-10Epub Date: 2024-12-09DOI: 10.1016/j.pnpbp.2024.111217
Hugo R Arias, Deborah Rudin, Dino Luethi, Jan Valenta, Anna Leśniak, Zofia Czartoryska, Agnieszka Olejarz-Maciej, Agata Doroz-Płonka, Dina Manetti, Philippe De Deurwaerdère, Maria Novella Romanelli, Jadwiga Handzlik, Matthias E Liechti, Abdeslam Chagraoui
The antidepressant-like activity of two psychoplastogens, ibogainalog (IBG) and ibogaminalog (DM506), was studied in naïve mice using the forced swim test (FST) and tail suspension test (TST). The behavioral results showed that a single administration of 25 mg/kg DM506 or 10 mg/kg IBG induced antidepressant-like activity in naïve mice in a volinanserin-sensitive manner that persisted for 72 h. Similar results were observed using the chronic immobilization stress (CIS) test, in which depression symptoms were reduced for 48 h. To assess the contribution of serotonergic and/or norepinephrinergic neurotransmission, serotonin (5-HT) and norepinephrine (NE) levels were depleted. The reduction in 5-HT levels, but not NE levels, inhibited the antidepressant-like activity of ibogalogs, suggesting that serotonergic transmission may play a more significant role than norepinephrinergic transmission. Concurrently, DM506, IBG, and TBG (derived from tabernanthine) inhibited monoamine transporters with the following order of selectivity: SERT > NE transporter > dopamine transporter. The IBG exhibited the highest selectivity for SERT. Only TBG inhibited monoamine oxidase A activity, indicating its relatively minor role. Radioligand and functional assays showed that all ibogalogs bind to the 5-HT2 receptor subfamily (DM506 > IBG > TBG) and fully activate 5-HT2A/2C receptors with similar potency in the nM range. However, they act as competitive antagonists of the 5-HT2B receptor, with DM506 as an exception, exhibiting partial but potent agonist activity. In conclusion, ibogalogs induce acute and sustained antidepressant-like activity in naïve and depressed mice through mechanisms involving 5-HT2A receptor activation and serotonergic transmission.
{"title":"The psychoplastogens ibogaminalog and ibogainalog induce antidepressant-like activity in naïve and depressed mice by mechanisms involving 5-HT<sub>2A</sub> receptor activation and serotonergic transmission.","authors":"Hugo R Arias, Deborah Rudin, Dino Luethi, Jan Valenta, Anna Leśniak, Zofia Czartoryska, Agnieszka Olejarz-Maciej, Agata Doroz-Płonka, Dina Manetti, Philippe De Deurwaerdère, Maria Novella Romanelli, Jadwiga Handzlik, Matthias E Liechti, Abdeslam Chagraoui","doi":"10.1016/j.pnpbp.2024.111217","DOIUrl":"10.1016/j.pnpbp.2024.111217","url":null,"abstract":"<p><p>The antidepressant-like activity of two psychoplastogens, ibogainalog (IBG) and ibogaminalog (DM506), was studied in naïve mice using the forced swim test (FST) and tail suspension test (TST). The behavioral results showed that a single administration of 25 mg/kg DM506 or 10 mg/kg IBG induced antidepressant-like activity in naïve mice in a volinanserin-sensitive manner that persisted for 72 h. Similar results were observed using the chronic immobilization stress (CIS) test, in which depression symptoms were reduced for 48 h. To assess the contribution of serotonergic and/or norepinephrinergic neurotransmission, serotonin (5-HT) and norepinephrine (NE) levels were depleted. The reduction in 5-HT levels, but not NE levels, inhibited the antidepressant-like activity of ibogalogs, suggesting that serotonergic transmission may play a more significant role than norepinephrinergic transmission. Concurrently, DM506, IBG, and TBG (derived from tabernanthine) inhibited monoamine transporters with the following order of selectivity: SERT > NE transporter > dopamine transporter. The IBG exhibited the highest selectivity for SERT. Only TBG inhibited monoamine oxidase A activity, indicating its relatively minor role. Radioligand and functional assays showed that all ibogalogs bind to the 5-HT<sub>2</sub> receptor subfamily (DM506 > IBG > TBG) and fully activate 5-HT<sub>2A/2C</sub> receptors with similar potency in the nM range. However, they act as competitive antagonists of the 5-HT<sub>2B</sub> receptor, with DM506 as an exception, exhibiting partial but potent agonist activity. In conclusion, ibogalogs induce acute and sustained antidepressant-like activity in naïve and depressed mice through mechanisms involving 5-HT<sub>2A</sub> receptor activation and serotonergic transmission.</p>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":" ","pages":"111217"},"PeriodicalIF":5.3,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-10DOI: 10.1016/j.pnpbp.2024.111209
Haobo Zhang , Haonan Sun , Jiatao Li , Zhangwei Lv , Yun Tian , Xu Lei
Previous research has found brain structural and functional abnormalities in patients with insomnia disorder (ID). However, the relationship between brain abnormalities in ID and brain gene expression is unclear. This study explored the relationship between gene expression and brain structural or functional abnormalities in ID, and we validated the reliability of the results with two independent datasets (discover dataset: healthy control (HC) = 129, ID = 264; validation dataset: HC = 160, ID = 115). Brain imaging results show that ID has abnormal resting-state spontaneous activity, regional homogeneity, and widespread gray matter volume reduction compared to HC. The association analysis results with gene expression further revealed that brain function abnormalities in ID were significantly associated with gene expression, but structural abnormalities were not. This study establishes a link between transcriptional changes and brain functional abnormalities in ID, revealing a genetic basis that may involve several biological pathways. Specifically, these pathways include hormonal regulation of the hypothalamic-pituitary-adrenal (HPA) axis, which plays a crucial role in stress response and sleep regulation; ion transport across membranes, vital for neuronal communication; and inhibitory neuronal regulation, essential for maintaining normal brain function. Furthermore, the ID-related genes are enriched for brain tissue and cortical cells, emphasizing their relevance in understanding the biological underpinnings of ID.
{"title":"Gene expression is associated with brain function of insomnia disorder, rather than brain structure","authors":"Haobo Zhang , Haonan Sun , Jiatao Li , Zhangwei Lv , Yun Tian , Xu Lei","doi":"10.1016/j.pnpbp.2024.111209","DOIUrl":"10.1016/j.pnpbp.2024.111209","url":null,"abstract":"<div><div>Previous research has found brain structural and functional abnormalities in patients with insomnia disorder (ID). However, the relationship between brain abnormalities in ID and brain gene expression is unclear. This study explored the relationship between gene expression and brain structural or functional abnormalities in ID, and we validated the reliability of the results with two independent datasets (discover dataset: healthy control (HC) = 129, ID = 264; validation dataset: HC = 160, ID = 115). Brain imaging results show that ID has abnormal resting-state spontaneous activity, regional homogeneity, and widespread gray matter volume reduction compared to HC. The association analysis results with gene expression further revealed that brain function abnormalities in ID were significantly associated with gene expression, but structural abnormalities were not. This study establishes a link between transcriptional changes and brain functional abnormalities in ID, revealing a genetic basis that may involve several biological pathways. Specifically, these pathways include hormonal regulation of the hypothalamic-pituitary-adrenal (HPA) axis, which plays a crucial role in stress response and sleep regulation; ion transport across membranes, vital for neuronal communication; and inhibitory neuronal regulation, essential for maintaining normal brain function. Furthermore, the ID-related genes are enriched for brain tissue and cortical cells, emphasizing their relevance in understanding the biological underpinnings of ID.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"136 ","pages":"Article 111209"},"PeriodicalIF":5.3,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142774694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号